|[March 07, 2013]
Research and Markets: PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/tsnzn2/pharmapoint)
has announced the addition of GlobalData's new report "PharmaPoint:
Epilepsy - UK Drug Forecast and Market Analysis to 2022" to their
GlobalData has released its new Country report, PharmaPoint: Epilepsy -
UK Drug Forecast and Market Analysis to 2022. Epilepsy is a brain
disorder characterized by spontaneously occurring and recurrent
seizures. The market is heavily driven by the sales of antiepileptic
drugs (AEDs) targeted at seizure reduction. The AED market is currently
dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both
drugs have experienced significant generic erosion, thy form the
mainstay of epilepsy treatment in the nine markets and will continue to
have significant market share during the forecast period. Other key
drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's
Depakote, and Novartis' Tegretol and Trileptal which still have
significant usage due to their longevity in the market. However, the AED
dominance landscape will continue to shift towards newer generation
drugs particularly following the recent market entry of
GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer
first-in-class mechanisms of action.
The main driver for growth in this market is the launch of new AEDs and
the continued uptake of recent AEDs, although this is affected by
government pricing and reimbursement regulations.
- Overview of Epilepsy including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on the key drugs in the UK including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the UK Epilesy market.
For more information visit http://www.researchandmarkets.com/research/tsnzn2/pharmapoint
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]